Glenn Dubin - 01 Apr 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
01 Apr 2024
Net transactions value
+$11,000
Form type
4
Filing time
02 Apr 2024, 16:34:29 UTC
Previous filing
03 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $11,000 +1,358 +6.6% $8.10 22,075 01 Apr 2024 Direct F1, F2
holding CCCC Common Stock 770,607 01 Apr 2024 By DF Investment Partners LLC F3
holding CCCC Common Stock 20,000 01 Apr 2024 By G&E Dubin Family Foundation F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024.
F3 Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein.
F4 Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.